Search

Competing Interests: Competing interests:: Bahaa Abu-Raya reports honoraria for participation in meetings from Sanofi, and is coinvestigator on studies funded by GSK, Pfizer, Merck, Moderna, Vaccitech, and Inventprise. Joanne Langley reports funding for clinical trials from GSK, Pfizer, Merck, Moderna, Sanofi, and Sequris, paid to Dalhousie University; consulting fees from GSK, Sanofi, Enanta, and Sequris, paid to departmental academic funds; and travel support from Sanofi, Enanta, and Sequris. She reports participation on a data safety monitoring board for a pneumococcal vaccine trial with Vaxcyte and the SNAP trial. She is medical advisor for the Nova Scotia Palivizumab for RSV Prevention Program and a member of a working group on influenza with the National Advisory Committee on Immunization. Pascal Lavoie is medical director of the British Columbia RSV Immunoprophylaxis Program and is employed by the Provincial Health Services Authority of British Columbia. He received honoraria for participating in an advisory board for Sanofi Canada. No other competing interests were declared.

Competing Interests: Competing interests:: Bahaa Abu-Raya reports honoraria for participation in meetings from Sanofi, and is co-investigator on studies funded by GSK, Pfizer, Merck, Moderna, Vaccitech, and Inventprise. Joanne Langley reports funding for clinical trials from GSK, Pfizer, Merck, Moderna, Sanofi, and Sequris, paid to Dalhousie University; consulting fees from GSK, Sanofi, Enanta, and Sequris, paid to departmental academic funds; and travel support from Sanofi, Enanta, and Sequris. She reports participation on a data safety monitoring board for a pneumococcal vaccine trial with Vaxcyte and the SNAP trial. She is a medical advisor for the Nova Scotia Palivizumab for RSV Prevention Program and a member of a working group on influenza with the National Advisory Committee on Immunization. Pascal Lavoie is medical director of the British Columbia RSV Immunoprophylaxis Program and is employed by the Provincial Health Services Authority of British Columbia. He received honoraria for participating in an advisory board for Sanofi Canada. No other competing interests were declared.

Competing Interests: Intérêts concurrents: Soren Gantt reçoit des honoraires de consultant de Moderna, de Merck, de GlaxoSmithKline et de Curevo; du financement pour la recherche sur les vaccins de Merck, de GlaxoSmithKline et de VBI Vaccines; et du financement pour l’essai d’un vaccin contre la COVID-19 de Symvivo. Soren Gantt est également membre ayant droit de vote du Comité consultatif national de l’immunisation. Manish Sadarangani a pris part à des projets de recherche financés par Pfizer, Merck, Seqirus, Sanofi Pasteur, VBI Vaccines et GlaxoSmithKline, et a reçu du financement pour l’essai d’un vaccin contre la COVID-19 de Symvivo. Tous les fonds ont été versés à son établissement; il n’a reçu aucun honoraire personnel. Aucun autre intérêt concurrent n’a été déclaré.

Competing Interests: Competing interests: Soren Gantt receives consulting fees related to vaccines from Moderna, Merck, GlaxoSmithKline and Curevo; research funding for vaccine research from Merck, GlaxoSmithKline and VBI; and research funding for a COVID-19 vaccine trial from Symvivo. Soren Gantt is also a voting member of the Canadian National Advisory Committee on Immunization. Manish Sadarangani has been an investigator on projects funded by Pfizer, Merck, Seqirus, Sanofi Pasteur, VBI Vaccines and GlaxoSmithKline, and has received research funding for a COVID-19 vaccine trial from Symvivo. All funds have been paid to his institution, and he has not received any personal payments. No other competing interests were declared.